Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Cardiol. Jun 26, 2013; 5(6): 196-206
Published online Jun 26, 2013. doi: 10.4330/wjc.v5.i6.196
Table 3 Description of derivation and validation samples
CharacteristicDerivation sample (n = 1050)Validation sample (n = 852)
Age (yr)67.9 ± 13.567.9 ± 13.6
Male gender686 (64.7)578 (68.0)
Type of myocardial infarction
STEMI42.1%38.8%
NSTEMI57.9%61.2%
Diabetes mellitus380 (35.9)266 (31.2)
Previous hypertension796 (75.2)631 (74.2)
Hyperlipidemia59629 (56.3)475 (59.6)
Smoking habits287 (27.1)281 (33.1)
Previously known coronary disease283 (26.7)243 (28.6)
History of stroke/TIA94 (9.0)77 (9.1)
Atrial fibrillation at admission144 (13.7)99 (12.4)
Admission killip class  1.40 ± 0.61.36 ± 0.7
Maximum killip class 1.56 ± 0.81.46 ± 0.8
Average number of vessels with significant lesions1.60 ± 0.97 1.54 ± 0.99
GFR at admission68.6 ± 38.472.6 ± 32.0
BUN at admission (mmol/L)9.58 ± 6.818.85 ± 6.20
Hemoglobin at admission (mg/dL)  13.3 ± 2.113.8 ± 6.14
NT-proBNP at admission (ng/L)  4202 ± 134006393 ± 15950
Submitted to revascularization procedures645 (61.4)663 (77.8)
Clinically significant bleeding during hospitalization87 (8.3)55 (6.5)
Average GRACE score for intrahospital mortality153.9 (P25 124; P50 151; P75 179)145.6 (P25 114; P50 143; P75 173)
Average GRACE score for 6-mo mortality128.0 (P25 102; P50 125; P75 149)121.0 (P25 94; P50 118; P75 145)
Moderate-severe left ventricular systolic dysfunction19.50%23.00%
Discharged on dual anti-platelet therapy818 (89.2)723 (90.6)
Discharged on anticoagulant treatment36 (3.9)37 (4.6)
Intrahospital mortality8.60%6.10%
Post-discharge mortality (mo)165 (16.5) (Follow-up: 19.9 ± 6.7)88 (11.0) (Follow-up: 13.4 ± 8.1)
Bleeding events during follow-up (mo)62 (6.8) (Follow-up: 19.9 ± 6.7)60 (7.5) (Follow-up: 13.4 ± 8.1)